Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Dec 21, 2009; 15(47): 5946-5952
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Table 3 Baseline characteristics of the patients enrolled in the molecular study (mean ± SD) n (%)
| PR group (n = 9) | PK group (n = 9) | PRK group (n = 9) | P-value | |
| Age (yr) | 42 ± 13 | 54 ± 9 | 42 ± 12 | 0.04 |
| Sex (M/F) | 5/4 | 4/5 | 5/4 | NS |
| HCV-RNA × 103 IU/mL | 263 ± 232 | 1032 ± 878 | 1742 ± 1392 | 0.01 |
| HCV-RNA > 700 × 103 IU/mL | 1 (27) | 4 (44) | 7 (78) | 0.02 |
| ALT (U/L) | 70 ± 21 | 80 ± 27 | 100 ± 57 | NS |
| ETR | 7 (78) | 5 (56) | 6 (67) | NS |
| SVR | 5 (56) | 3 (33) | 5 (56) | NS |
- Citation: Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. World J Gastroenterol 2009; 15(47): 5946-5952
- URL: https://www.wjgnet.com/1007-9327/full/v15/i47/5946.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5946